SILAHIGH SIGNALFINANCIAL10-K

Sila Realty Trust experienced a substantial decline in operating income while total liabilities increased significantly, indicating potential operational or asset valuation challenges.

The company's core profitability has been meaningfully impacted, with operating income declining substantially year-over-year, suggesting either reduced rental income, higher operating expenses, or asset impairments. The concurrent 26% increase in total liabilities alongside reduced cash flows creates a concerning financial picture that requires close monitoring of the company's ability to service its debt obligations and maintain dividend coverage.

Comparing 2026-02-25 vs 2025-03-03View on EDGAR →
FINANCIAL ANALYSIS

Sila Realty Trust's financial performance deteriorated notably, with operating income declining substantially while total liabilities grew by over $159 million to $763.2 million. Operating cash flow declined modestly by 10.3% to $119.1 million, and the company significantly reduced share buybacks from $61.5 million to $8.6 million, suggesting management is conserving cash. The combination of reduced profitability, higher leverage, and lower cash generation signals potential stress in the healthcare REIT's portfolio performance.

FINANCIAL STATEMENT CHANGES
Share Buybacks
Cash Flow
-86%
$61.5M→$8.6M

Buyback activity reduced 86% — capital being redeployed elsewhere or cash conservation underway.

Operating Income
P&L
-61.3%
$92.4M→$35.7M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Total Liabilities
Balance Sheet
+26.4%
$603.9M→$763.2M

Liabilities increased 26.4% — monitor debt-to-equity ratio and interest coverage.

Net Income
P&L
-22.4%
$42.7M→$33.1M

Net income declined 22.4% — review whether driven by operations, interest costs, or non-recurring items.

Cash & Equivalents
Balance Sheet
-19%
$39.8M→$32.3M

Cash decreased 19% — monitor burn rate and upcoming capital needs.

Operating Cash Flow
Cash Flow
-10.3%
$132.8M→$119.1M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

LANGUAGE CHANGES
NEW — 2026-02-25
PRIOR — 2025-03-03
ADDED
As of February 18, 2026, there were 55,246,390 shares of common stock of Sila Realty Trust, Inc.
Market for Registrant s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 26 Item 6.
s business is conducted through Sila Realty Operating Partnership, LP, a Delaware limited partnership, or the Operating Partnership.
We are an internally managed company primarily focused on investing in the growing and resilient healthcare sector.
We invest in high quality net lease healthcare facilities across the continuum of care, in the pursuit of generating predictable, durable and growing income streams.
Our properties include, among others, medical outpatient buildings, inpatient rehabilitation facilities and surgical and specialty facilities.
On June 13, 2024, our common stock, par value $0.01 per share, or our Common Stock, was listed and began trading on the New York Stock Exchange, or the NYSE, under the ticker symbol SILA .
As of December 31, 2025, we owned 140 real estate healthcare properties and three undeveloped land parcels, including the Stoughton Healthcare Facility which has been taken out of service and is being demolished.
Key Developments During 2025 We purchased six operating healthcare properties, comprising approximately 241,000 rentable square feet for an aggregate purchase price of approximately $148,877,000.
We fully funded two mezzanine loans for the development of an inpatient rehabilitation facility and a behavioral healthcare facility in Lynchburg, Virginia, or the Mezzanine Loans.
REMOVED
As of February 24, 2025, there were 55,143,443 shares of common stock of Sila Realty Trust, Inc.
Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 27 Item 6.
Substantially all of Sila Realty Trust, Inc.'s business is conducted through Sila Realty Operating Partnership, LP, a Delaware limited partnership, or the Operating Partnership.
We are an internally managed company primarily focused on investing in high quality healthcare facilities across the continuum of care, which we believe typically generate predictable, durable and growing income streams.
New York Stock Exchange Listing and Reverse Stock Split On June 13, 2024, our common stock, par value $0.01 per share, or our Common Stock, was listed and began trading on the New York Stock Exchange, or the NYSE, under the ticker symbol "SILA", or the Listing.
Upon the Listing, all outstanding shares of Class I Common Stock and Class T Common Stock were automatically converted into shares of Class A Common Stock on a one-for-one basis and authorized but unissued shares of Class I Common Stock, Class T Common Stock and Class T2 Common Stock were reclassified into additional shares of Class A Common Stock.
Class A Common Stock was then immediately renamed Common Stock and is the sole class of stock traded on the NYSE.
On April 8, 2024, in anticipation of the Listing, we amended our charter to effect a one-for-four reverse stock split, or the Reverse Stock Split, of each issued and outstanding share of each class of our Common Stock, effective May 1, 2024, and we also amended our charter to decrease the par value of each issued and outstanding share of our Common Stock from $0.04 par value per share to $0.01 par value per share immediately after the Reverse Stock Split.
In addition, equitable adjustments were made to the maximum number of shares of our Common Stock that may be issued pursuant to our Amended and Restated 2014 Restricted Share Plan, or the A R Incentive Plan, to reflect the Reverse Stock Split.
The Reverse Stock Split affected all record holders of our Common Stock uniformly and did not affect any record holder s percentage ownership interest.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →